

# FETAL PERICARDIOCENTESIS

**\*Raquel Garcia Rodriguez, Raquel Garcia Delgado,  
Luciana Obreros Zegarra, Yonit Emergui Zhrizen, Marta Armas Roca,  
Margarita Castellano Medina, Jose Angel Garcia Hernandez**

*Prenatal Diagnosis and Fetal Medicine Unit, Obstetrics and Gynecology Service,  
Hospital Universitario Materno Infantil de Canarias, Las Palmas de Gran Canaria, Spain*

*\*Correspondence to raquelgarciarod@gmail.com*

**Disclosure:** The authors have declared no conflicts of interest.

**Received:** 04.03.16 **Accepted:** 16.11.16

**Citation:** EMJ. 2017;2[3]:98-104.

---

## ABSTRACT

Fetal pericardiocentesis is a safe and effective procedure that is used to drain pericardial effusion in selected fetuses. The aim of the procedure is to reduce the risk of pulmonary hypoplasia, the development of cardiac tamponade and fetal hydrops, and in some cases to allow fetal lung maturity, improving fetal extraction with a better haemodynamic and respiratory condition. In this review, we discuss the indications, technical procedure, and the outcomes of the fetal pericardiocentesis reported in the literature.

Keywords: Pericardiocentesis, pericardial effusion, cardiac tumours, pulmonary hypoplasia.

---

## INTRODUCTION

The pericardium is a double-walled fibroelastic sac containing the heart and origin of the great vessels. It consists of two layers: an outer or parietal layer and an inner or visceral layer. The pericardium prevents sudden dilation of the heart, especially the right side, and heart and great vessel displacement; it minimises heart friction with the surrounding structures and prevents the spread of infection or cancer cells from the lung and pleura. In between the two layers there is a small amount of fluid, a plasma ultrafiltrate produced by the visceral layer. This liquid facilitates friction-free movement of the heart during systole and diastole within the pericardial sac. During ventricular systole, the pericardial space around the ventricles expands and the pericardial fluid moves into this expanding space, and during ventricular diastole, the pericardial space around the ventricles disappears as the pericardial fluid moves away from the field of view. This phasic movement is characteristically demonstrated by a colour Doppler signal within the pericardial space opposite to the direction of the colour Doppler signal seen within the ventricles.<sup>1</sup>

## PERICARDIAL EFFUSION

### Definition

The sonographic finding of fluid with an amount of <2 mm is frequent during ultrasound examination and is seen in >40–50% of normal fetuses, especially when the ultrasound beams are perpendicular to the ventricular walls. This finding has no clinical significance and is not considered to be pericardial effusion.<sup>1-4</sup>

Pericardial effusion is defined on ultrasound examination when the heart is partially or completely surrounded by liquid that is seen in all projections, is usually present around the atrioventricular groove, and the larger region is >2 mm<sup>5,6</sup> and surpasses the atrioventricular union. If it measures <4 mm it is considered small and if it measures >4 mm it is considered large.<sup>7</sup> In cases of massive pericardial effusion, a posterior displacement of the lungs can be found on the four-chamber view (Figure 1). The main differential diagnosis is pleural effusion, which appears on sonography, a fluid layer surrounding the lungs.

### Aetiopathogenesis


Pericardial effusion can be found isolated or associated with different abnormalities described

in the literature (Table 1). The incidence is about 0.64–2.00%.<sup>6,8</sup> It is necessary to perform a comprehensive fetal study ultrasound to rule out the different causes to which it is associated. In most cases the effusion occurs as a manifestation of fetal hydrops (immune or non-immune), which is necessary to discard.<sup>5</sup> The mechanisms for development of pericardial effusion can be transudative (obstruction of lymphatic drainage, increased lymphatic pressure) or exudative (secondary to inflammation, infection, malignancy, or autoimmune). The pathogenesis depends on the cause.

A complete sonographic evaluation of the fetus and maternal blood tests must be performed to determine the presence of abnormal group

antibodies, rule out viral infections, fetomaternal haemorrhage, and in some cases amniocentesis for karyotyping and umbilical blood sampling to confirm the presence of anaemia and viral infections. If no causes are found the pericardial effusion is transient and idiopathic, with a better prognosis, and almost 45% of the cases will resolve spontaneously.<sup>8</sup>

For cases of high-output cardiac failure secondary to fetal anaemia, arrhythmias, or congenital heart disease, studies should be performed to make the differential diagnosis. In cases of fetal anaemia, pericardial effusion is an early sign of hydrops, or appears in a hydropic fetus, which should be treated to resolve the fetal condition.



**Figure 1: Fetal echocardiography.**

A) Large pericardial effusion (white star) associated with fetal cardiac diverticulum at 15 weeks of gestation (continuous arrow); B) Large pericardial effusion (white star) associated with fetal anaemia; C) Differential diagnosis with pleural effusion showing the fluid around the lungs (white dot); D) Large pericardial effusion (white star) associated with cardiac teratoma at 32 weeks of gestation (discontinuous arrow); E) Pericardiocentesis in this fetus at 32 weeks, the needle crosses the fetal thorax (dotted line arrow).

**Table 1: Causes of pericardial effusion.**

Cardiac abnormalities
Cardiac malformation
Arrhythmia
Cardiac tumours: teratoma, rhabdomyoma
Hydrops
Immune
Non-immune
Cardiac abnormalities
Infections: parvovirus B19, cytomegalovirus
Anaemia
Arrhythmia
Cardiomyopathy
Miscellaneous: mediastinal teratoma, lymphohistiocytosis
Placental chorioangioma
Infections
Cytomegalovirus, parvovirus B19
Anaemia
Intrauterine growth restriction
Aneuploidy
Placental haemorrhage
Cerebral abnormalities
Intracranial haemorrhage
Subdural haematoma
Thorax abnormalities
Congenital cystic adenomatoid malformation
Congenital diaphragmatic hernia
Vascular abnormalities
Haemangioma
Hepatic haemangioendothelioma
Portohepatic shunt
Kasabach-Merritt syndrome
Abdominal wall malformations
Omphalocele
Pentalogy of Cantrell
Genitourinary malformation
Polycystic kidney disease
Multicystic dysplastic kidney
Posterior urethral valve syndrome
Hypospadias
Spinal malformation
Sacroccocygeal teratoma
Transient pericardial effusions

*Adapted from Kyeong et al.<sup>8</sup>*

In the case of cardiac teratomas, the pericardial effusion is probably due to the irritative stimulus of the tumour on the pericardial layers and rupture of the cystic areas in the pericardium caused by the multicystic nature of pericardial teratomas. Furthermore, the tumour can cause mechanical obstruction of the venous return and the thoracic duct which interferes with the lymphatic drainage,

leading to the development of pericardial, pleural effusions, ascites, and fetal hydrops. Oesophageal compression can cause polyhydramnios. Pericardial effusion and mass effect are responsible for fetal pericardial tamponade.<sup>9</sup>

Pericardial effusion is rarely associated with another cardiac tumour. Some cases of cardiac rhabdomyomas with pericardial effusion have been described in literature due to the rapidly growing mass and the development of cardiac arrhythmia. There are few cases associated with fibromas and cardiac haemangiomas.<sup>8,10,11</sup> In cases of pericardial effusion associated with cardiac diverticula, it is believed to be caused by the rubbing of the diverticulum with the pericardium walls.

## PERICARDIOCENTESIS

### Definition

Fetal pericardiocentesis is the removal of fluid with a percutaneous catheter or needle from the pericardial sac. It is a safe and effective method to drain the effusion. It must be performed after 16 weeks of gestational age to avoid complications, just as with amniocentesis.

### Indications

The aim of pericardiocentesis is to decompress the fetal chest, allowing the expansion of the lungs, reducing the pressure in the fetal venous system, causing a theoretical risk reduction for pulmonary hypoplasia and fetal hydrops.

Depending on the aetiology, for some cases a single procedure may resolve the condition. There have been reports in the literature of spontaneous resolution especially in idiopathic cases, but also in cases associated with cardiac diverticula.<sup>5,8,12,13</sup> Since pericardiocentesis is considered a technique with a low risk to the fetus, it should be the treatment of choice in selected cases, such as large pericardial effusions that do not disappear or increase in a short period of time, to avoid the risk of pulmonary hypoplasia with severe sequelae to the fetus.<sup>12</sup> For fetuses with moderate pericardial effusions outpatient follow-up should be done according to the underlying cause and fetal status, which may require weekly controls or controls every 48 hours.

In isolated pericardial effusion, the persistence of pericardial effusion is more important than the size. In some studies there were no correlations between the size of the pericardial effusion

and the regression of pericardial fluid, adverse outcomes, or mortality rate.<sup>5,6,8</sup> The pericardial effusion associated with cardiac tumours, usually teratomas, benefits from performing an intrauterine pericardiocentesis.<sup>9,14-16</sup> The decompression of the pericardial cavity reduces the risk that the fetus may develop non-immune fetal hydrops. In these cases, intrauterine pericardiocentesis can help to reduce fetal hydrops with prolongation of pregnancy until lung maturity is reached, which prevents or delays the development of cardiac tamponade or pericardial effusion relapse. The use of pericardiocentesis immediately prior to delivery improves ventilation and haemodynamic stability in the preterm infant, prevents severe cardiorespiratory distress, facilitates neonatal stabilisation and intubation, and allows planned rather than emergency cardiothoracic surgery.<sup>15-18</sup>

It has been proposed that fetuses with cardiac tumours such as teratomas must be followed to assess the presence of fetal hydrops. In cases where hydrops develops and the fetus is >28-30 weeks and matured, delivery and postnatal intervention could be considered. In cases where there is insufficient lung maturity, pericardiocentesis can be performed to delay delivery for 1-2 weeks and allow time to mature the fetus before delivery. For fetuses <28 weeks old with severe pericardial effusion it is recommended to perform pericardiocentesis and if the effusion recurs, it is sometimes necessary to perform this procedure again<sup>16,19</sup> and serial pericardiocentesis may be required to avoid prematurity with its related complications.<sup>12,20-23</sup> Therefore, the aetiology associated with the pericardial effusion, gestational age, and fetal status should be taken into consideration to assess the need for fetal lung maturation with corticosteroids. We do not consider that fetal lung maturation is required in all cases <34 weeks of gestational age just because the procedure is being performed, but it should be considered in those cases where fetal status is compromised and could require an immediate delivery if fetal deterioration occurred. There have been reported cases in which a pericardial-amniotic shunt was placed and, in some cases, associated with pericardiocentesis. However, there are limited data available and further evaluation of its efficacy is needed.<sup>12,24</sup>

## Technique

Fetal pericardiocentesis should be performed under sonographic guidance as an outpatient procedure.

Two people are needed for the procedure: an operator to control the needle and transducer, and an assistant to help in aspiration of the fluid.

A fetal ultrasound should be performed initially to locate the most suitable place for puncture. The mother should be positioned as horizontally as possible, to allow better access to the amniotic cavity. Skin preparation with antiseptic solution and sterile field placement should be performed. The ultrasound probe should be prepared with an antiseptic solution prior to each procedure, since the probe is not covered with a sterile drape. We use a multi-frequency convex transducer with a 60x13 mm footprint and a 2-7 MHz bandwidth.

With a short 22-gauge needle, local anaesthesia is administered at the puncture site and with the local anaesthetic needle, a preliminary exploration to confirm the direction of the needle approach is made. Then, under direct visualisation a 20-22-gauge needle should be used to access the fetal chest. We recommend using a 20-gauge needle just as when performing amniocentesis. The puncture needle is gently inserted in the maternal skin and advanced through the uterus, amniotic cavity, and fetal chest under echographic guidance. Then, with a syringe, the fluid should be drained and finally the needle removed under echographic visualisation. The complete procedure must be performed with ultrasound guidance with continuous visualisation of the needle. Follow-up is performed every 48 hours during the first week, and after that the follow-up interval will be determined by the underlying condition that caused the effusion and fetal status.

If the woman is rhesus negative, anti-D immunoglobulin should be given within 72 hours after the procedure. If the amniotic fluid amount is too low to allow an adequate visualisation for the technique, an amnioinfusion is performed by administering saline through the puncture needle once the amniotic cavity has been reached.

## Complications

To date, pericardiocentesis is a safe and effective procedure. The main complications are related to the amnion puncture, like with amniocentesis: temporary loss of amniotic fluid and premature rupture of membranes (PROM). Other rare complications are fetal injuries, vertical transmission of infectious diseases, intrauterine infection, pregnancy loss, and, rarely, septic shock.

**Table 2: Reported cases of fetal pericardiocentesis.**

Reference	Cause	GE PC (weeks)	Prenatal evolution	Outcome/postnatal evolution
Cavalle-Garrido <sup>29</sup>	CD	20	No recurrence of PE	Full-term live birth. Asymptomatic at 12 months old
Johnson et al. <sup>30</sup>	CD	20	No recurrence of PE	Full-term live birth. Asymptomatic at 16 months old; no treatment
Bernasconi et al. <sup>25</sup>	CD	25	Intrauterine fetal death	Cardiac diverticulum rupture
McAuliffe et al. <sup>31</sup>	CD	16	No recurrence of PE	Full-term live birth. Asymptomatic at 10 months old. No treatment
McAuliffe et al. <sup>31</sup>	CD	14	No recurrence of PE	Full-term live birth. Asymptomatic at 8 months old; no treatment
Prefumo et al. <sup>32</sup>	CD	16	No recurrence of PE	Full-term live birth. Asymptomatic at 22 months old; no treatment
Gardiner et al. <sup>33</sup>	CD	14	No recurrence of PE	Full-term live birth; asymptomatic; no treatment
Carrard et al. <sup>34</sup>	CD	17	No recurrence of PE	Full-term live birth; asymptomatic at 11 months old; no treatment
Abi-Nader et al. <sup>35</sup>	CD	24	No recurrence of PE	Full-term live birth; asymptomatic at 12 months old; no treatment
Barberato et al. <sup>26</sup>	CD	20	Enlargement of PE	Prenatal fetal death at 37 weeks
Williams et al. <sup>36</sup>	CD	18	Relapse 1 week later and subsequent spontaneous resolution at Week 32-33	-
Garcia Rodriguez et al. <sup>13</sup>	CD	17	No PE recurrence	Full-term live birth. Asymptomatic at birth. Healthy at 5 years old
Zeng et al. <sup>37</sup>	CD	20	-	Live birth. Asymptomatic
Zeng et al. <sup>37</sup>	CD	24	-	Live birth. Asymptomatic
Antifólo et al. <sup>27</sup>	CDH	21, 22+4	No PE recurrence	Caesarean at 37 weeks gestation. EXIT procedure. Thoracic surgery with correction of the defect 2 hours after birth. Asymptomatic at 18 days old
Kanamori et al. <sup>28</sup>	CDH	27	Small PE	Live birth at 36 weeks. Thorax surgery to correct the defect. Asymptomatic at 11 months old
Benatar et al. <sup>9</sup>	T	33	Small PE recurrence	Live birth at 37 weeks. Spontaneous onset of labour. Caesarean for transverse presentation. Cardiac surgery after stabilisation. Healthy at 2 months old
Iacona et al. <sup>18</sup>	T	32, 33, 34	Recurrence of the PE	Live birth at 34 weeks. Induction of labour. Vaginal delivery. No cardiorespiratory compromise after birth
Sklansky et al. <sup>23</sup>	T	24, 27	Recurrence of the PE	Live birth at 35 weeks. Caesarean. Cardiac surgery at birth. Asymptomatic at 12 months old
Bruch et al. <sup>15</sup>	T	28	Recurrence of PE, develop of hydrops,	Live birth at 34 weeks. Caesarean. Cardiac surgery at birth
Paw and Jamieson <sup>20</sup>	T	Multiple PC	Deterioration of the hydropic condition	Live birth at 34 weeks. Caesarean. Cardiac surgery after stabilisation. Asymptomatic at discharge
Fujimori et al. <sup>38</sup>	T	34	Improvement at 3 days after PC. Deterioration of the hydropic condition	Live birth at 37 weeks. Caesarean. Cardiac surgery. Asymptomatic at 6 months old
Sepulveda et al. <sup>17</sup>	T	37, 37+4	Improvement at 4 days after PC but recurrence afterwards	Live birth at 37+4 weeks. Caesarean. Cardiac surgery on the first day. Asymptomatic at 6 days old
Pratt et al. <sup>39</sup>	T	28	-	Live birth at 34 weeks. Caesarean. Cardiac surgery on the first day. Asymptomatic at 3 years old
Laquay et al. <sup>40</sup>	T	34	Deterioration of the hydrops at 2 days	Live birth at 34+2 weeks. Cardiac surgery on the 3 days. Asymptomatic at 3 months old

**Table 2 continued.**

Reference	Cause	GE PC (weeks)	Prenatal evolution	Outcome/postnatal evolution
Laquay et al. <sup>40</sup>	T	28	-	Live birth at 32 weeks. Spontaneous onset of labour. Caesarean. Cardiac surgery at 3 days old. Asymptomatic at 3 months old
Tollens et al. <sup>41</sup>	T	33	Recurrence of PE and risk of hydrops development	Live birth at 36 weeks. Caesarean. Cardiac surgery after stabilisation. Asymptomatic at 3 years old
Kamil et al. <sup>21</sup>	T	28+2,30+1+31+1, 32, 32+6	Improvement after PC but recurrence afterwards	Live birth at 34 weeks. Caesarean. PC after delivery. Cardiac surgery 4 days after delivery. Asymptomatic at 12 months old
Czernik et al. <sup>22</sup>	T	27, 28, 29, 31	Improvement at 3 days after PC but recurrence afterwards	Live birth at 31+5 weeks, premature rupture membranes and pathological fetal heart rate tracing. PC after birth. Cardiac surgery at 3 days old
Goldberg et al. <sup>42</sup>	T	31	-	Live birth at 31 weeks. Cardiac surgery on Day 2 of life. Asymptomatic at discharge
Michailidis et al. <sup>43</sup>	CGD	33	Recurrence at 35 weeks	Live birth at 35 weeks. PC after birth. Widespread pustular lesions. Antibiotic treatment
Walsh et al. <sup>44</sup>	KH	34+5	-	Live birth at 38 weeks. Induction of labour. PC after birth. Surgery at 7 weeks old

GE PC: gestational age of the pericardiocentesis; PC: pericardiocentesis; CD: cardiac diverticulum; CDH: congenital diaphragmatic hernia (Morgagni); T: cardiac teratoma; PE: pericardial effusion; CGD: chronic granulomatous disease; KH: kaposiform haemangioendothelioma.

## REVIEW OF THE LITERATURE

We performed a PubMed search and reviewed the literature for cases with pericardiocentesis performed prenatally. Patients who underwent drainage by placing shunts additional to pericardiocentesis were excluded, and cases where only pericardiocentesis was performed as a pericardial effusion treatment were studied. **Table 2** summarises the cases where pericardiocentesis was performed.

At the time of writing, 33 cases of prenatal intrauterine pericardiocentesis have been reported. In 14 cases, pericardial effusion was associated with cardiac diverticulum, 14 cases to cardiac teratoma, 2 cases to congenital diaphragmatic hernia (intrapericardial hernia or Morgagni's hernia), 1 case of kaposiform haemangioendothelioma, and 1 case of X-linked chronic granulomatous disease. In cardiac diverticula, the pericardial effusion was resolved with a simple pericardiocentesis. For cardiac teratomas eight cases used a single pericardiocentesis to drain the effusion and for six fetuses the use of serial pericardiocentesis was necessary.

There were no complications reported in relation to the pericardiocentesis, but in one case of cardiac teratoma, PROM occurred at 31 weeks. In this fetus a total of four pericardiocenteses were performed: three prior to PROM to improve fetal status associated with hydrops, extending *in utero* life for 4 weeks and allowing fetal lung maturation with corticosteroids at 29 weeks; and one pericardiocentesis performed prior to delivery at 31+5 weeks.<sup>22</sup> Two fetal deaths were reported in association with cardiac diverticulum. In one case this was due to diverticulum rupture<sup>27</sup> and in the other case it occurred 17 weeks after the procedure.<sup>33</sup>

Neonatal survival was high. All live neonates (n=31) were asymptomatic at hospital discharge. In the two cases of intrapericardial congenital diaphragmatic hernia (Morgagni) with pericardial effusion, the procedure avoided the development of pulmonary hypoplasia and avoided neonatal respiratory morbidity and fetal death.<sup>36,37</sup> In conclusion, fetal pericardiocentesis is a safe procedure allowing the possibility of fetal lung maturation and improving fetal extraction with a better haemodynamic and respiratory condition at delivery.

## REFERENCES

1. Yoo SL et al. Normal pericardial fluid in the fetus: color and spectral Doppler analysis. *Ultrasound Obstet Gynecol.* 2001;18(3):248-52.
2. Brown DL et al. Sonography of the fetal heart: normal variants and pitfalls. *AJR Am J Roentgenol.* 1993;160(6):1251-5.
3. Jeanty P et al. Fetal pericardial fluid: A normal finding of the second half of gestation. *Am J Obstet Gynecol.* 1984;149(5):529-32.
4. Dizon-Townson DS et al. A prospective evaluation of fetal pericardial fluid in 506 second-trimester low-risk pregnancies. *Obstet Gynecol.* 1997;90(6):958-61.
5. Shenker L et al. Fetal pericardial effusion. *Am J Obstet Gynecol.* 1989;160(6):1505-8.
6. Di Salvo DN et al. Clinical significance of isolated fetal pericardial effusion. *J Ultrasound Med.* 1994;13(4):291-3.
7. Slesnick TC et al. Characteristic and outcomes of fetuses with pericardial effusions. *Am J Cardiol.* 2005;96(4):599-601.
8. Kyeong KS et al. Clinical outcomes of prenatally diagnosed cases of isolated and nonisolated pericardial effusion. *Fetal Diagn Ther.* 2014;36(4):320-5.
9. Benatar A et al. Prenatal pericardiocentesis: its role in the management of intrapericardial teratoma. *Obstet Gynecol.* 1992;79(5 Pt 2):856-9.
10. Schlaegel F et al. Prenatal diagnosis of giant cardiac rhabdomyoma with fetal hydrops in tuberous sclerosis. *J Prenat Med.* 2013;7(3):39-41.
11. Niewiadomska-Jarosik K et al. Prenatal diagnosis and follow-up of 23 cases of cardiac tumors. *Prenat Diagn.* 2010;30(9):882-7.
12. Devlieger R et al. Therapy for foetal pericardial tumours: survival following in utero shunting, and literature review. *Fetal Diagn Ther.* 2009;25(4):407-12.
13. Garcia Rodriguez R et al. Prenatal Diagnosis of Cardiac Diverticulum with Pericardial Effusion in the First Trimester of Pregnancy with Resolution after Early Pericardiocentesis. *Case Rep Obstet Gynecol.* 2015;2015:154690.
14. Todros T et al. Management of a fetus with intrapericardial teratoma diagnosed in utero. *J Ultrasound Med.* 1991;10(5):287-90.
15. Bruch SW et al. Prenatal therapy for pericardial teratomas. *J Pediatr Surg.* 1997;23(7):1113-5.
16. Tollens T et al. Fetal cardiac tamponade due to an intrapericardial teratoma. *Ann Thorac Surg.* 1998;66(2):559-60.
17. Sepulveda W et al. Intrapericardial teratoma. *Ultrasound Obstet Gynecol.* 2000;15(6):547-8.
18. Iacona GM et al. Intrapericardial teratoma in a low birth weight preterm infant: a successful multidisciplinary approach. *Interact Cardiovasc Thorac Surg.* 2011;12(2):287-9.
19. Sydorak RM et al. Prenatal resection of a fetal pericardial teratoma. *Fetal Diagn Ther.* 2002;17(5):281-5.
20. Paw PT, Jamieson SW. Surgical Management of intrapericardial teratoma diagnosed in utero. *Ann Thorac Surg.* 1997;64(2):552-4.
21. Kamil D et al. Fetal pericardial teratoma causing cardiac insufficiency: prenatal diagnosis and therapy. *Ultrasound Obstet Gynecol.* 2006;28(7):972-8.
22. Czernik C et al. Hydrops fetalis caused by a large intrapericardial teratoma. *Ultrasound Obstet Gynecol.* 2006;28(7):973-6.
23. Sklansky M et al. Intrapericardial teratoma in a twin fetus: diagnosis and management. *Obstet Gynecol.* 1997;89(5 pt 2):807-9.
24. Bader R et al. Fetal pericardial teratoma: presentation of two cases and review of the literature. *Am J Perinatol.* 2006;23(1):53-8.
25. Bernasconi A et al. Prenatal rupture of a left ventricular diverticulum: a case report and review of the literature. *Prenat Diagn.* 2004;24(7):504-7.
26. Barberato MF et al. Prenatal diagnosis of left ventricular aneurysm and diverticulum. *Arq Bras Cardiol.* 2009;93(2):e36-8.
27. Antiñolo G et al. Diagnosis and management of fetal intrapericardial Morgagni diaphragmatic hernia with massive pericardial effusion. *J Pediatr Surg.* 2010;45(2):424-6.
28. Kanamori Y et al. A case of intrapericardial diaphragmatic hernia with a massive pericardial effusion: fetal diagnosis and therapy. *J Pediatr Surg.* 2005;40(11):e43-5.
29. Cavalle-Garrido T. Evolution of fetal ventricular aneurysms and diverticula of the heart: an echocardiographic study. *Am J Perinatal.* 1997;14(7):393-400.
30. Johnson JA et al. Prenatal diagnosis of a fetal ventricular diverticulum associated with pericardial effusion: successful outcome following pericardiocentesis. *Prenat Diagn.* 1996;16(10):954-7.
31. McAuliffe FM et al. Cardiac diverticulum with pericardial effusion: report of two new cases treated by in-utero pericardiocentesis and a review of the literature. *Ultrasound Obstet Gynecol.* 2005;25(4):401-4.
32. Prefumo F et al. Fetal congenital cardiac diverticulum with pericardial effusion: two cases with different presentations in the first trimester of pregnancy. *Ultrasound Obstet Gynecol.* 2005;25(4):405-8.
33. Gardiner HM et al. Images in cardiovascular medicine. Pericardiocentesis at 14 weeks: effective treatment of pericardial effusion complicating right ventricular diverticulum. *Circulation.* 2005;112(9):e120.
34. Carrard C et al. Fetal right ventricular diverticulum with pericardial effusion: report of a new case treated by in utero pericardiocentesis. *Pediatr Cardiol.* 2010;31(6):891-3.
35. Abi-Nader K et al. Successful outcome after prenatal treatment of a cardiac diverticulum with massive pericardial effusion. *Fetal Diagn Ther.* 2009;25(1):148-52.
36. Williams JA et al. Prenatally diagnosed right ventricular outpouchings: a case series and review of the literature. *Pediatr Cardiol.* 2009;30(6):840-5.
37. Zeng S et al. Features and outcome of fetal cardiac aneurysms and diverticula: a single center experience in China. *Prenat Diagn.* 2016;36(1):68-73.
38. Fujimori K et al. Prenatal diagnosis of intrapericardial teratoma: a case report. *J Obstet Gynaecol Res.* 1999;25(2):133-6.
39. Pratt JW et al. Neonatal intrapericardial teratomas: clinical and surgical considerations. *Cardiol Young.* 2000;10:27-31.
40. Laquay N et al. Intrapericardial teratoma in newborn babies. *Eur J Cardiothorac Surg.* 2003;23(4):642-4.
41. Tollens M et al. Pericardial teratoma: prenatal diagnosis and course. *Fetal Diagn Ther.* 2003;18(6):432-6.
42. Goldberg SP et al. Surgical management of intrapericardial teratoma in the fetus. *J Pediatr.* 2010;156(5):848-9.
43. Michailidis GD et al. In-utero pericardiocentesis to treat fetal hydrops caused by X-linked chronic granulomatous disease. *Ultrasound Obstet Gynecol.* 2006;28(1):117-9.
44. Walsh MA et al. Kaposiform hemangioendothelioma presenting antenatally with a pericardial effusion. *J Pediatr Hematol Oncol.* 2008;30(10):761-3.